Effectiveness of Bivalent Boosters Over Nine and Half Months in Nebraska
Paritala, S.; Xu, Y.; Du, Y.; Donahue, M.; Maloney, P.; Lin, D.-Y.
Show abstract
On September 1, 2022, Moderna and Pfizer-BioNTech bivalent vaccines replaced existing monovalent vaccines as booster doses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for persons aged 12 and older in the United States. We assessed the effectiveness of these bivalent boosters against Omicron infection and severe outcomes (COVID-19 hospitalization and death) over a 9.5-month period using line-level data from the state of Nebraska. We found that the relative effectiveness of bivalent boosters, compared with one fewer vaccine dose, against Omicron infection and subsequent death was 39.0% (95% confidence interval [CI], 35.7 to 42.2) and 70.0% (95% CI, 38.8 to 85.3), respectively, at four weeks post administration and gradually waned afterward. Vaccine effectiveness was broadly similar against different Omicron subvariants.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea 96%
- Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis 96%
- Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting 96%
Similar papers in this journal
- Initial protection against Omicron in children and adolescents by BNT162b2 96%
- Safety Monitoring of mRNA Vaccines Administered During the Initial 6 Months of the U.S. COVID-19 Vaccination Program: Reports to Vaccine Adverse Events Reporting System (VAERS) and v-safe 95%
- Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial 95%
Similar papers in this journal
- Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar 96%
- Protection offered by mRNA-1273 versus BNT162b2 vaccines against SARS-CoV-2 infection and severe COVID-19 in Qatar 96%
- Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar 96%
Similar papers in this journal
- Estimation of COVID-19 cases prevented by vaccination in California 96%
- Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19 95%
- Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort study 95%
Similar papers in this journal
- Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial 95%
- Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials 95%
- Real-world Effectiveness of BNT162b2 in Children and Adolescents in Preventing Infection and Severe Diseases with SARS-CoV-2 During the Delta and Omicron Periods: Findings from Trial Emulation Using an EHR-based Cohort 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.